Q3 Earnings Estimate for ImmunityBio Issued By HC Wainwright

Posted by Francis Steltz on Nov 11th, 2026

ImmunityBio, Inc. (NASDAQ:IBRX – Free Report) – HC Wainwright lowered their Q3 2026 earnings per share (EPS) estimates for shares of ImmunityBio in a research note issued on Monday, November 9th. HC Wainwright analyst A. Maldonado now expects that the company will post earnings per share of ($0.18) for the quarter, down from their previous forecast of ($0.06). HC Wainwright currently has a “Buy” rating and a $15.00 target price on the stock. The consensus estimate for ImmunityBio’s current full-year earnings is ($0.30) per share. HC Wainwright also issued estimates for ImmunityBio’s Q4 2026 earnings at ($0.19) EPS, FY2026 earnings at ($0.52) EPS, Q1 2027 earnings at ($0.19) EPS, Q2 2027 earnings at ($0.19) EPS, Q3 2027 earnings at ($0.18) EPS, Q4 2027 earnings at ($0.18) EPS, FY2027 earnings at ($0.74) EPS, FY2028 earnings at ($0.02) EPS, FY2029 earnings at $0.51 EPS and FY2030 earnings at $1.28 EPS.

Other equities research analysts have also recently issued research reports about the company. Piper Sandler reiterated an “overweight” rating and set a $16.00 price objective on shares of ImmunityBio in a research note on Wednesday, October 14th. Jefferies Financial Group boosted their target price on shares of ImmunityBio from $12.00 to $14.00 and gave the stock a “buy” rating in a report on Wednesday, October 14th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of ImmunityBio in a report on Tuesday, October 6th. Six analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, ImmunityBio currently has a consensus rating of “Moderate Buy” and an average target price of $16.00.

Check Out Our Latest Research Report on ImmunityBio

ImmunityBio Stock Down 5.2%

IBRX stock opened at $6.74 on Wednesday. The business has a 50 day moving average price of $8.70 and a two-hundred day moving average price of $7.96. The company has a market cap of $7.14 billion, a price-to-earnings ratio of -6.24 and a beta of 0.17. ImmunityBio has a twelve month low of $1.95 and a twelve month high of $12.43.

Insider Activity at ImmunityBio

In other ImmunityBio news, Director Cheryl Cohen sold 81,056 shares of the company’s stock in a transaction that occurred on Friday, October 2nd. The stock was sold at an average price of $10.50, for a total value of $851,088.00. Following the sale, the director owned 100,309 shares in the company, valued at $1,053,244.50. This represents a 44.69% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Barry Simon sold 25,000 shares of the firm’s stock in a transaction that occurred on Monday, October 5th. The shares were sold at an average price of $10.75, for a total value of $268,750.00. Following the completion of the sale, the director directly owned 2,777,788 shares of the company’s stock, valued at approximately $29,861,221. The trade was a 0.89% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 66.10% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On ImmunityBio

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. BlackRock Inc. lifted its stake in shares of ImmunityBio by 29.4% during the 2nd quarter. BlackRock Inc. now owns 34,083,262 shares of the company’s stock worth $298,399,000 after buying an additional 7,736,819 shares during the last quarter. State Street Corp boosted its holdings in shares of ImmunityBio by 20.8% during the second quarter. State Street Corp now owns 21,398,438 shares of the company’s stock worth $187,343,000 after acquiring an additional 3,690,335 shares during the period. SEB Asset Management AB bought a new stake in shares of ImmunityBio during the first quarter worth approximately $18,770,000. Bank of America Corp DE acquired a new position in shares of ImmunityBio in the second quarter valued at approximately $19,125,000. Finally, Royal Bank of Canada grew its position in shares of ImmunityBio by 1,731.8% in the first quarter. Royal Bank of Canada now owns 1,486,049 shares of the company’s stock valued at $11,399,000 after purchasing an additional 1,404,922 shares during the last quarter. 8.58% of the stock is owned by institutional investors.

Key Stories Impacting ImmunityBio

Here are the key news stories impacting ImmunityBio this week:

Positive Sentiment: ANKTIVA plus BCG met the primary endpoint in a randomized trial for BCG-naïve, high-grade non-muscle-invasive bladder cancer, supporting the treatment’s potential in an additional patient group. Article: ANKTIVA trial results
Positive Sentiment: The company reported expanded FDA approval and additional international approval for ANKTIVA plus BCG, broadening its commercial opportunity. Article: Q3 results and approvals
Neutral Sentiment: Third-quarter product revenue rose 53% year over year to about $48.7 million, while U.S. revenue for the first nine months increased 92%. However, quarterly sales declined from the prior quarter. Article: Q3 results
Negative Sentiment: Results missed estimates: ImmunityBio reported a loss of about $0.09 per share versus an expected $0.07 loss, and revenue of about $48.8 million versus forecasts of $59.2 million. A wider loss, rising expenses, and the sequential sales decline weighed on sentiment. Article: Q3 earnings miss
Negative Sentiment: The company disclosed “substantial doubt” about its ability to continue operating without additional funding, raising concern about potential financing or dilution. Its valuation relative to sales may also leave little room for execution setbacks. Article: Earnings, valuation, and funding concerns

ImmunityBio Company Profile

(Get Free Report)

ImmunityBio is a biotechnology company that develops immunotherapies for cancer and infectious diseases. Its research combines approaches including immune-modulating biologics, cell therapies and vaccine-based treatments, with a focus on activating the body’s natural and adaptive immune responses. The company’s lead product, Anktiva (nogapendekin alfa inbakicept-pmln), received U.S. Food and Drug Administration approval in 2024 for use with Bacillus Calmette-Guérin (BCG) in adults with BCG-unresponsive non-muscle-invasive bladder cancer with carcinoma in situ, with or without papillary tumors.